

ARENA PHARMACEUTICALS INC

Form 8-K

February 29, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): February 29, 2016

Arena Pharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter)

|   |                             |   |
|---|-----------------------------|---|
| Delaware  | 000-31161                   | 23-2908305                              |
| (State or other jurisdiction<br>of incorporation)             | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |
| 6154 Nancy Ridge Drive, San Diego, California 92121           |                             |   |
| (Address of principal executive offices) (Zip Code)           |                             |   |
| 858.453.7200  |                             |   |
| (Registrant's telephone number, including area code)          |                             |   |
| N/A   |                             |   |
| (Former name or former address, if changed since last report) |                             |   |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

In this report, “Arena Pharmaceuticals,” “Arena,” “Company,” “we,” “us” and “our” refer to Arena Pharmaceuticals, Inc., and/or one or more of our wholly owned subsidiaries, unless the context otherwise provides. Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.

Item 2.02 Results of Operations and Financial Condition.

On February 29, 2016, we issued a press release reporting our financial results for the fourth quarter and full year ended December 31, 2015. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release issued February 29, 2016, reporting financial results for the fourth quarter and full year ended December 31, 2015

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 29, 2016 Arena Pharmaceuticals, Inc.

By: /s/ Steven W. Spector

Steven W. Spector

Executive Vice President, General Counsel and  
Secretary

EXHIBIT INDEX

| Exhibit No. | Description  |
|-------------|--|
| 99.1        | Press release issued February 29, 2016, reporting financial results for the fourth quarter and full year ended December 31, 2015 |